Background: Glioblastoma multiforme (GBM) is the most common subtype of primary brain tumors and it is characterized by aggressive biologic behaviors. Many chemotherapeutics have been extensively studied to prolong patient survival but only temozolomide (TMZ) in combination with radiotherapy demonstrated survival benefit to date. Therefore, there have been clinical unmet needs for effective and safe anti-cancer drugs in the treatment of GBM. In this study, we identified novel curcumin mimics which show synergetic antitumor effects with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) against human glioblastoma cells. Also, we investigated anticancer mechanisms of these compounds. Methods: Newly synthesized curcumin mimics (11a-11k) with 2-ethylamino groups in the chalcone backbone and variously substituted triazole side chains were obtained using Huisgen 1,3-cycloaddition reaction between alkynes and an intermediate. In lactate dehydrogenase (LDH) release assay, we performed co-treatment of TRAIL or curcumin mimics against human CRT-MG astroglioma cells. And western blot analysis was performed to analyze the expression of proteins involved in the apoptotic process. Results: Our novel curcumin mimics (11a, 11c, 11h, and 11j) showed effective stimulation of TRAIL-induced cytotoxicity and mild cytotoxicity when they were administered alone. Furthermore, the compound 11c, one of the potent drug candidates, has been screened for its mechanism of action. Exposure to this analogue for 24 hours induced cleavage of caspase-8, caspase-3, and poly (ADP-ribose) polymerase (PARP) in astroglioma cells. It also suppressed inhibitor of apoptosis protein (IAP) expressions. Conclusion: Our findings suggest that curcumin mimics were promising TRAIL-sensitizers with minimal toxicities against human glioblastoma cells. And these compounds played a key role on both intrinsic and extrinsic apoptotic pathways. 
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O1 À 7 À 3 Induction chemotherapy with paranasal sinus cancer for management of the orbit Background: Paranasal sinus cancers often extend into the orbit and the intra-orbital extension is thought to affect prognosis of the tumor. In case of intra-orbital extension of the cancers, surgical treatments including the orbital evisceration are usually selected, while chemo radiotherapy (CRT) is performed for the patients who would not like to have a surgery. Recently intra-arterial cisplatin and concomitant radiation therapy is attracting attentions as an organ preserving treatment option. It achieves good local control with orbital preservations. However, the effects of induction chemotherapy (ICT) on the organ preservation have not been well discussed. The purpose of this study was to investigate the effects of systemic chemotherapy for paranasal sinus cancers extending into the orbit on the orbital preservation. Methods: Twenty patients with locally advanced paranasal cancer extending to the orbit were treated from 2006 to 2016 at our hospital. The treatment and their oncological outcomes were reviewed. Results: Of the 20 patients, 17 patients had maxillary sinus cancer. Twelve lesions (60%) were diagnosed as T4a, and 8 lesions (40%) as T4b. Regarding N classification, 10 patients (50%) were diagnosed as N0, 2(10%) as N1, 6 (30%) as N2b, and 2 (10%) as N2c. Sixteen patients (80%) were treated with ICT followed by surgery or CRT while the remainders had definitive radiation or CRT. Complete response (CR) and partial response (PR) were achieved in 1 (6%) and 5 (31%) patients respectively. Seven patients had the surgery after ICT, and R0 resection was achieved in 3 patients (43%). The 3-year disease free survival for patients of PR/CR was 100%, 60% for patients of stable/progressive disease after ICT, in contrast to 50% for patients without ICT. The orbital preservation was achieved in 14(88%) of 16 patients who treated with ICT. Conclusions: ICT has a potential to contribute to orbital preservation in the treatment of paranasal sinus cancers.
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